Туберкульоз. Адаптована клінічна настанова, заснована на доказах (стр. 111 )

242. Gupta DK, Kumar R, Nath N, Kothari AK. Chemoprophylaxis in high risk children-analysis of 8 years' follow up: preliminary report. Indian Journal ofTubercutosis 1993;40:125-127,

243. Ormerod LP, Rifampicin and isoniazid prophylactic chemotherapy for tuberculosis. Archives of Disease in Childhood 1998:78(2): 169-171.

244. Bucher HC, Griffith LE, Guyatt GH, Sudre P et al. Isoniazid prophylaxis for tuberculosis in HIV infection; a meta-analysis of randomized controlled trials. AIDS 1999;13(4):501-507.

245. Wilkinson D, Squire SB, Garner P. Effect of preventive treatment for tuberculosis in adults infected with HIV: systematic review of randomised placebo controlled trials. British Medical Journal 1998;317(7159):625-629.

246. Woldehanna S, Volmiaik J. Treatment of latent tuberculosis infection in HIV infected persons. The Cochrane Library 2OO4;[l):CD0O0H71.

247. Wilkinson D. Drugs for preventing tuberculosis in HIV infected persons. The Cochrane Library 2000;(4).

248. American Thoracic Society and the Centers for Disease Control and Prevention. Targeted tuberculin testing and treatment of latent tuberculosis infection. American Journal of Respiratory &• Critical Care Medicine 2000;I61(4 Pt 2):S221-S247.

249. Fatal and severe hepatitis associated with rifampin and pyrazinamide for the treatment of latent tuberculosis infection - New York and Georgia, 2000. Morbidity & Mortality Weekly Report 2001;50(15):289-291.

250. American Thoracic Society and the Centers for Disease Control and Prevention. Fatal and severe liver injuries associated with rifampin and pyrazinamide for latent tuberculosis infection Morbidity & Mortality Weekly Report 200T;50(34):733-735.

251. Lee AM, Mennone JZ, Jones RC, Paul WS. Risk factors for hepatotoxicity associated with rifampin and pyrazinamide for the treatment of latent tuberculosis infection: experience from three public health tuberculosis clinics. International Journal of Tuberculosis & Lung Disease 2002;6( 11 ):995-1000.

252. Enarson DA. 'The epidemiological basis of tuberculosis control'. In: Clinical tuberculosis, London, Chapman & Hall, 1998.

253. Dye C, Scheele S, Dolin P, Pathania V, Raviglione MC. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project. Journal of the American Medical Association 1999;282(7):677-686.

254. Cohn DL, El Sadr WM. 'Treatment of latent tuberculosis infection'. In: Tuberculosis: a comprehensive international approach. Second ed. New York: Marcel Dekker, 2000.

255. Sehvyn PA, Hartel D, Lewis VA, Schoenbaum EE et al A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. New England Journal of Medicine 1989;320(9):545-550.

256. Ferebee SH, Controlled chemoprophylaxis trials in tuberculosis: a general review. Bibliotheai Tuberculosa 1970;26:28-106,

therland I, Svandova E, Radhakrishna S. The development of clinical tuberculosis following infection with tubercle bacilli. Tubercle 1982;63(4);255-268.

258. Falk A, Fuchs GF. Prophylaxis with isoniazid in inactive tuberculosis: a veterans administration cooperative study XII. Chest 1978;73(l):44-48.

259. Steinbruck P, Dankova D, Edwards LB, Doster B, Livesay VT. The risk of tuberculosis in patients with fibrous lesions radiologically diagnosed (French], Bulletin of the International Union Against Tuberculosis 1972;47:144-171.

260. Palmer C, Jablon S, Edwards P. Tuberculosis morbidity of young men in relation to tuberculin sensitivity and body build. American Review of Tuberculosis 1957;76(4):517-539.

261. Lichtenstein 1H, MacGregor RR. Mycobacterial infections in renal transplant recipients: report of five cases and review of the literature. Review of Infectious Diseases 1983;5(2):216-226,

262. Munoz P, Palomo ], Munoz R, Rodriguez-Creixems M et al Tuberculosis in heart transplant recipients. Clinical Infectious Diseases 1995;21(2):398-402.

263. Korner MM, Hirata N, Tenderich G, Minami K et al. Tuberculosis in heart transplant recipients. Chest 1997;lll(2):365-369.

264. Pickleman JR, Evans LS, Kane JM, Freeark R], Tuberculosis after jejunoileal bypass for obesity. Journal of the American Medical Association 1975;234(7):744.

265. Bruce RM, Wise L. Tuberculosis after jejunoileal bypass for obesity. Annals of Interna! Medicine 1977;87(5):S74-576.

266. Paul R, Silicosis in Northern Rhodesia copper miners. Archives of Environmental Health 1961;2:96-109.

267. Lundhi AP, Adler AJ, Berlyne GM, Friedman EA. Tuberculosis in patients undergoing maintenance hemodialysis. American Journal of Medicine 1979;67(4):597«602.

268. Qua S, Karim M, Elwood RK, FitzGerald JM. Risk of tuberculosis in dialysis patients: a population-based study. International Journal of Tuberculosis & Lung Disease 1998;2(12):989-991.

269. Andrew OT, Schoenfeld PY, Hopewell PC, Humphreys MH. Tuberculosis in patients with end-stage renal disease. American Journal of Medicine 1980;68(l):59-65.

270. Thorn P, Brookes V, Waterhouse J. Peptic ulcer, partial gastrectomy, and pulmonary tuberculosis. British Medical Journal 1956;(4967):603-608.

271. Snider DE. Tuberculosis and gastrectomy. Chest 1985;87(4}:414-415.

272. Steiger Z, Nickel WO, Shannon GJ, Nedwicki EG, Higgins RF. Pulmonary tuberculosis after gastric resection. American Journal of Surgery 1976;131(6):668—671.

273. Pablos-Mendez A, Blustein J, Knirsch CA. The role of diabetes meihtus in the higher prevalence of tuberculosis among Hispanics. American Journal of Public Health 1997;87(4);574-579.

274. Boucot K, Dillon E, Cooper D, Meier P, Richardson R. Tuberculosis among diabetics: the Philadelphia survey. American Review of Tuberculosis 1952;65(l:2):l-50.

275. Oscarsson PR Silwar H. Incidence of pulmonary tubereculosis among diabetics: search among diabetics in the county of Kristianstad. Acta Medica Scandinavia 1958;16)(SuppI 335):23~48.

276. Keane J, Gershon S, Wise RP, Mirabile-Levens E et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. New England Journal of Medicine 2001;345(15):1098-1104.

277. Wolfe F, Midland K, Anderson J, Urbansky K. Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy. Arthritis & Rheumatism 2004;50(2):372—379.

278. The Britisli Thoracic Association. A study of a standardised contact procedure in tuberculosis. Tubercle 1978;59(4);245~259,

279. Milstien JB, Gibson JJ. Quality control of BCG vaccine by WHO: a review of factors that may influence vaccine effectiveness and safety. Bulletin of the World Health Organization I990;68(i):93-108.

280. Fine PE. BaciEe Calmette-Guerin vaccines: a rough guide. Clinical Infectious Diseases 1995;20(1):11-14,

281. Wilson ME, Fineberg HV, Colditz GA. Geographic latitude and the efficacy of bacillus Calmette-Guerin vaccine. Clinical Infectious Diseases 1995;20(4):982-991.

282. Trial of BCG vaccines in south India for tuberculosis prevention: first report - Tuberculosis Prevention Trial. Bulletin of the World Health Organization 1979;57(5):819~827.

283. Packe GE, Innes JA. Protective effect of BCG vaccination in infant Asians: a case control study. Archives of Disease in Childhood 1988;63(3):277-281.

284. Hart PD, Surtherland I, Thomas J. The immunity conferred by effective BCG and vole bacillus vaccines, in relation to individual variations in induced tuberculin sensitivity and to technical variations in the vaccines. Tubercle 1967;48:201-210.

285. Hart PD, Sutherland I, BCG and vole bacillus vaccines in the prevention of tuberculosis in adolescence and early adult life: final report to the Medical Research Council. British Medical Journal 1977;2(6Q82):293~295,

286. Aronson NE, Santosham M, Comstock GW, Howard RS et al. Long-term efficacy of BCG vaccine in American Indians and Alaska Natives: a 60-year follow-up study. Journal of the American Medical Association 20Q4\291{l7):2W6-209l.

287. Joseph CA, Watson JM, Fern KJ. BCG immunisation in England and Wales: a survey of policy and practice in schoolchildren and neonates, British Medical Journal 1992;305(68S2):495-498.

288. Colditz GA, Berkey CS, Mosteller F, Brewer TF et al. The efficacy of bacillus Calmette-Guerin vaccination of newborns and infants in the prevention of tuberculosis: meta-analyses of the published literature. Pediatrics 1995;96(l;Pt ]):29-35.

289. Wasz-Hockert 0, Genz H, Landmann H, Ocklitz HW. The effects of systematic BCG vaccination of newborn on the incidence of post-primary tuberculous meningitis in childhood. Padiatrie und Gratzgebictc 1969i2%(6)'M5-370.

290. Altet Gomez MN, Alcaide MJ, Canela SJ, Serra ML, Salieras SL. Retrospective evaluation of the efficacy of the BCG vaccination campaign of newborns in Barcelona, Spain. Tubercle & Lung Disease 1993;74(2):100-105.

291. Criteria for discontinuation of vaccination programmes using Bacille Calmette-Guerin (BCG) in countries with a low prevalence of tuberculosis; a statement of the International Union Against Tuberculosis and Lung Disease. Tubercle & Lung Disease 1994;75{3}:179-180.

therland I. Effectiveness of BCG vaccination in England and Wales in 1983. Tubercle 1987;68(2): 81-92.

therland I, Springett VH. The effects of the scheme for BCG vaccination of schoolchildren in England and Wales and the consequences of discontinuing the scheme at various dates. Journal of Epidemiology & Community Health 1989;43( 1): 15-24.

294. Ormerod LP, Charlett A, Gilham C, Darbyshire JH, Watson JM. Geographical distribution of tuberculosis notifications in national surveys of England and Wales in 1988 and 1993: report of the Public Health Laboratory Service/British Thoracic Society/Department of Health Collaborative Group. Thorax 1998;53(3):176-181.